Company intelligence / Profile preview

VAIM Global

Ownership: Private
Employees: ~150
Development stage: Commercial

Overview

Juvelook and Juvelook Volume, the company’s flagship products, are commercialized hybrid bio-stimulator injectables composed of PDLLA and HA. They are used for facial rejuvenation and volume restoration, with clinical use by medical professionals in aesthetic medicine. The company has applied for patents on its proprietary polymer particle manufacturing methods. Clinical results focus on improved collagen generation, safety, and efficacy in cosmetic procedures[6].

Therapeutic areas: Dermatology
Modalities: Injectable collagen-stimulating fillers (hybrid bio-stimulators)PDLLA (Poly-D,L-Lactic Acid)HA (Hyaluronic Acid)
Industry: Implantable Medical Devices

Drug pipeline

2 assets

Juvelook

Commercial

Indications: Skin rejuvenation, Fine wrinkles, Volume loss

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on VAIM Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VAIM Global.

Explore the full profile